{"id":"esmolol","rwe":[{"pmid":"41870838","year":"2026","title":"What If We Let It Fibrillate? New Perspective on Atrial Fibrillation in Sepsis.","finding":"","journal":"Current medical science","studyType":"Clinical Study"},{"pmid":"41835717","year":"2026","title":"Severe Hypoglycemia-Induced Seizure in a Four-Year-Old Following Initiation of Nadolol for Supraventricular Tachycardia.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41763668","year":"2026","title":"Anaesthetic management of neurogenic atrial fibrillation with rapid ventricular response in a patient undergoing decompressive hemicraniectomy.","finding":"","journal":"BMJ case reports","studyType":"Clinical Study"},{"pmid":"41736776","year":"2026","title":"Vasoactive drugs and the distribution of crystalloid fluid during acute sepsis.","finding":"","journal":"Journal of intensive medicine","studyType":"Clinical Study"},{"pmid":"41689856","year":"2026","title":"Inhibitory effects and molecular interaction analysis of emergency cardiac drugs on human serum paraoxonase 1: an integrated in vitro and in silico approach.","finding":"","journal":"Archives of physiology and biochemistry","studyType":"Clinical Study"}],"_fda":{"id":"91f3287c-e1f4-48a0-a37e-74da91240a2d","set_id":"017023a9-00f0-4284-861f-a3634d4fdb17","openfda":{"unii":["V05260LC8D"],"route":["INTRAVENOUS"],"rxcui":["1736546"],"spl_id":["91f3287c-e1f4-48a0-a37e-74da91240a2d"],"brand_name":["Esmolol Hydrochloride"],"spl_set_id":["017023a9-00f0-4284-861f-a3634d4fdb17"],"package_ndc":["68083-211-01","68083-211-25"],"product_ndc":["68083-211"],"generic_name":["ESMOLOL HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["ESMOLOL HYDROCHLORIDE"],"manufacturer_name":["Gland Pharma Limited"],"application_number":["ANDA208538"],"is_original_packager":[true]},"version":"5","pregnancy":["8.1 Pregnancy Esmolol hydrochloride has been shown to produce increased fetal resorptions with minimal maternal toxicity in rabbits when given in doses approximately 8 times the maximum human maintenance dose (300 mcg/kg/min). There are no adequate and well-controlled studies in pregnant women. Esmolol hydrochloride injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Teratogenicity studies in rats at intravenous dosages of esmolol hydrochloride up to 3000 mcg/kg/min (10 times the maximum human maintenance dosage) for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while a dosage of 10,000 mcg/kg/min produced maternal toxicity and lethality. In rabbits, intravenous dosages up to 1000 mcg/kg/min for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while 2500 mcg/kg/min produced minimal maternal toxicity and increased fetal resorptions."],"overdosage":["10 OVERDOSAGE 10.1 Signs and Symptoms of Overdose Overdoses of esmolol hydrochloride injection can cause cardiac and central nervous system effects. These effects may precipitate severe signs, symptoms, sequelae, and complications (for example, severe cardiac and respiratory failure, including shock and coma), and may be fatal. Continuous monitoring of the patient is required. Cardiac effects include bradycardia, atrioventricular block (1st -, 2nd -, 3rd degree), junctional rhythms, intraventricular conduction delays, decreased cardiac contractility, hypotension, cardiac failure (including cardiogenic shock), cardiac arrest/asystole, and pulseless electrical activity. Central nervous system effects include respiratory depression, seizures, sleep and mood disturbances, fatigue, lethargy, and coma. In addition, bronchospasm, mesenteric ischemia, peripheral cyanosis, hyperkalemia, and hypoglycemia (especially in children) may occur. 10.2 Treatment Recommendations Because of its approximately 9-minute elimination half-life, the first step in the management of toxicity should be to discontinue the esmolol hydrochloride infusion. Then, based on the observed clinical effects, consider the following general measures. Bradycardia Consider intravenous administration of atropine or another anticholinergic drug or cardiac pacing. Cardiac Failure Consider intravenous administration of a diuretic or digitalis glycoside. In shock resulting from inadequate cardiac contractility, consider intravenous administration of dopamine, dobutamine, isoproterenol, or inamrinone. Glucagon has been reported to be useful. Symptomatic hypotension Consider intravenous administration of fluids or vasopressor agents such as dopamine or norepinephrine. Bronchospasm Consider intravenous administration of a beta2 stimulating agent or a theophylline derivative. 10.3 Dilution Errors Massive accidental overdoses of esmolol hydrochloride injection have resulted from dilution errors. Some of these overdoses have been fatal while others resulted in permanent disability. Bolus doses in the range of 625 mg to 2.5 g (12.5 to 50 mg/kg) have been fatal. Patients have recovered completely from overdoses as high as 1.75 g given over one minute or doses of 7.5 g given over one hour for cardiovascular surgery. The patients who survived appear to be those whose circulation could be supported until the effects of esmolol hydrochloride injection resolved."],"description":["11 DESCRIPTION Esmolol hydrochloride injection is a beta adrenergic receptor blocker with a very short duration of action (elimination half-life is approximately 9 minutes). Esmolol hydrochloride is: (±)-Methyl p-[2-hydroxy-3-(isopropylamino) propoxy] hydrocinnamate hydrochloride and has the following structure: Esmolol hydrochloride has the empirical formula C 16 H 26 NO 4 Cl and a molecular weight of 331.8. It has one asymmetric center and exists as an enantiomeric pair. Esmolol hydrochloride is a white to off-white crystalline powder. It is a relatively hydrophilic compound which is very soluble in water and freely soluble in alcohol. Its partition coefficient (octanol/water) at pH 7.0 is 0.42 compared to 17.0 for propranolol. 11.1 Esmolol Hydrochloride Injection Dosage Forms Esmolol hydrochloride injection is a clear, colorless to light yellow, sterile, nonpyrogenic, iso-osmotic solution of esmolol hydrochloride in sodium chloride. The formulation is described in the table below: Table 4 Formulation for Esmolol Hydrochloride Injection Esmolol Hydrochloride, USP 10 mg/mL Sodium Chloride, USP 5.9 mg/mL Water for Injection, USP Q.S. to volume of 10 mL Sodium Acetate Trihydrate, USP 2.8 mg/mL Glacial Acetic Acid, USP 0.546 mg/mL Sodium Hydroxide Q.S. to adjust pH to 4.5 to 5.5 Hydrochloric Acid Q.S. to adjust pH to 4.5 to 5.5 Q.S. = Quantity sufficient esmolol-spl-structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied Esmolol hydrochloride injection, Ready-to-use vials are supplied as: NDC 68083-211-25 Esmolol hydrochloride injection 100 mg/10 mL (10 mg/mL) 10 mL single dose vial Package Factor 25 vials per carton 16.2 Storage Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] . Protect from freezing. Avoid excessive heat. Visually inspect the container."],"geriatric_use":["8.5 Geriatric Use Clinical studies of esmolol hydrochloride injection did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should usually start at the low end of the dosing range, reflecting greater frequency of decreased renal or cardiac function and of concomitant disease or other drug therapy."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of esmolol hydrochloride injection in pediatric patients have not been established."],"effective_time":"20230623","nursing_mothers":["8.3 Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from esmolol hydrochloride injection, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother."],"clinical_studies":["14 CLINICAL STUDIES Supraventricular Tachycardia In two multicenter, randomized, double-blind, controlled comparisons of esmolol hydrochloride injection with placebo and propranolol, maintenance doses of 50 to 300 mcg/kg/min of esmolol hydrochloride injection were found to be more effective than placebo and about as effective as propranolol, 3 to 6 mg given by bolus injections, in the treatment of supraventricular tachycardia, principally atrial fibrillation and atrial flutter. The majority of these patients developed their arrhythmias postoperatively. About 60 to 70% of the patients treated with esmolol hydrochloride injection developed either a 20% reduction in heart rate, a decrease in heart rate to less than 100 bpm, or, rarely, conversion to normal sinus rhythm and about 95% of these patients did so at a dosage of 200 mcg/kg/min or less. The average effective dosage of esmolol hydrochloride injection was approximately 100 mcg/kg/min in the two studies. Other multicenter baseline-controlled studies gave similar results. In the comparison with propranolol, about 50% of patients in both the esmolol hydrochloride injection and propranolol groups were on concomitant digoxin. Response rates were slightly higher with both beta blockers in the digoxin-treated patients. In all studies significant decreases of blood pressure occurred in 20 to 50% of patients, identified either as adverse reaction reports by investigators, or by observation of systolic pressure less than 90 mmHg or diastolic pressure less than 50 mmHg. The hypotension was symptomatic (mainly hyperhidrosis or dizziness) in about 12% of patients, and therapy was discontinued in about 11% of patients, about half of whom were symptomatic. Hypotension was more common with esmolol hydrochloride injection (53%) than with propranolol (17%). The hypotension was rapidly reversible with decreased infusion rate or after discontinuation of therapy with esmolol hydrochloride injection. For both esmolol hydrochloride injection and propranolol, hypotension was reported less frequently in patients receiving concomitant digoxin."],"pharmacodynamics":["12.2 Pharmacodynamics Clinical pharmacology studies in normal volunteers have confirmed the beta blocking activity of esmolol hydrochloride injection, showing reduction in heart rate at rest and during exercise, and attenuation of isoproterenol-induced increases in heart rate. Blood levels of esmolol hydrochloride injection have been shown to correlate with extent of beta blockade. After termination of infusion, substantial recovery from beta blockade is observed in 10 to 20 minutes. The acid metabolite of esmolol exhibits negligible pharmacological activity. In human electrophysiology studies, esmolol hydrochloride injection produced effects typical of a beta blocker: a decrease in the heart rate, increase in sinus cycle length, prolongation of the sinus node recovery time, prolongation of the AH interval during normal sinus rhythm and during atrial pacing, and an increase in antegrade Wenckebach cycle length. In patients undergoing radionuclide angiography, esmolol hydrochloride injection, at dosages of 200 mcg/kg/min, produced reductions in heart rate, systolic blood pressure, rate pressure product, left and right ventricular ejection fraction and cardiac index at rest, which were similar in magnitude to those produced by intravenous propranolol (4 mg). During exercise, esmolol hydrochloride injection produced reductions in heart rate, rate pressure product and cardiac index which were also similar to those produced by propranolol, but esmolol hydrochloride produced a significantly larger fall in systolic blood pressure. In patients undergoing cardiac catheterization, the maximum therapeutic dose of 300 mcg/kg/min of esmolol hydrochloride injection produced similar effects and, in addition, there were small, clinically insignificant increases in the left ventricular end diastolic pressure and pulmonary capillary wedge pressure. At 30 minutes after the discontinuation of esmolol hydrochloride infusion, all of the hemodynamic parameters had returned to pretreatment levels. The relative cardioselectivity of esmolol hydrochloride injection was demonstrated in 10 mildly asthmatic patients. Infusions of esmolol hydrochloride injection 100, 200 and 300 mcg/kg/min produced no significant increases in specific airway resistance compared to placebo. At 300 mcg/kg/min, esmolol hydrochloride injection produced slightly enhanced bronchomotor sensitivity to dry air stimulus. These effects were not clinically significant, and esmolol hydrochloride injection was well tolerated by all patients. Six of the patients also received intravenous propranolol, and at a dosage of 1 mg, two experienced significant, symptomatic bronchospasm requiring bronchodilator treatment. One other propranolol-treated patient also experienced dry air-induced bronchospasm. No adverse pulmonary effects were observed in patients with COPD who received therapeutic dosages of esmolol hydrochloride injection for treatment of supraventricular tachycardia (51 patients) or in perioperative settings (32 patients)."],"pharmacokinetics":["12.3 Pharmacokinetics Esmolol is rapidly metabolized by hydrolysis of the ester linkage, chiefly by the esterases in the cytosol of red blood cells and not by plasma cholinesterases or red cell membrane acetylcholinesterase. Total body clearance in man was found to be about 20 L/kg/hr, which is greater than cardiac output; thus the metabolism of esmolol is not limited by the rate of blood flow to metabolizing tissues such as the liver or affected by hepatic or renal blood flow. Esmolol has a rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes. Using an appropriate loading dose, steady-state blood levels of esmolol hydrochloride injection for dosages from 50 to 300 mcg/kg/min are obtained within five minutes. Steady-state is reached in about 30 minutes without the loading dose. Steady-state blood levels of esmolol increase linearly over this dosage range and elimination kinetics are dose-independent over this range. Steady-state blood levels are maintained during infusion but decrease rapidly after termination of the infusion. Because of its short half-life, blood levels of esmolol can be rapidly altered by increasing or decreasing the infusion rate and rapidly eliminated by discontinuing the infusion. Consistent with the high rate of blood-based metabolism of esmolol, less than 2% of the drug is excreted unchanged in the urine. Within 24 hours of the end of infusion, the acid metabolite of esmolol in urine accounts for approximately 73 to 88% of the dosage. Metabolism of esmolol results in the formation of the corresponding free acid and methanol. The acid metabolite has been shown in animals to have negligible activity and in normal volunteers its blood levels do not correspond to the level of beta blockade. The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate. After a 4 hour maintenance infusion of 150 mcg/kg, the plasma concentrations of esmolol are similar in subjects with normal renal function and in patients with ESRD on dialysis. The half-life of the acid metabolite of esmolol hydrochloride injection, which is primarily excreted unchanged by the kidney, is increased about 12-fold to 48 hours in patients with ESRD. The peak concentrations of the acid metabolite are doubled in ESRD. Methanol blood levels, monitored in subjects receiving esmolol hydrochloride injection for up to 6 hours at 300 mcg/kg/min and 24 hours at 150 mcg/kg/min, approximated endogenous levels and were less than 2% of levels usually associated with methanol toxicity. Esmolol hydrochloride injection has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound."],"adverse_reactions":["6 ADVERSE REACTIONS Most common adverse reactions (incidence >10%) are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Gland Pharma at 864-879-9994 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The following adverse reaction rates are based on use of esmolol hydrochloride injection in clinical trials involving 369 patients with supraventricular tachycardia and over 600 intraoperative and postoperative patients enrolled in clinical trials. Most adverse effects observed in controlled clinical trial settings have been mild and transient. The most important and common adverse effect has been hypotension [see Warnings and Precautions ( 5.1 )]. Deaths have been reported in post-marketing experience occurring during complex clinical states where esmolol hydrochloride injection was presumably being used simply to control ventricular rate [see Warnings and Precautions ( 5.5 )] . Table 3 Clinical Trial Adverse Reactions (Frequency ≥3%) System Organ Class (SOC) Preferred MedDRA Term Frequency VASCULAR DISORDERS Hypotension* Asymptomatic hypotension Symptomatic hypotension (hyperhidrosis, dizziness) 25% 12% GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Infusion site reactions (inflammation and induration) 8% GASTROINTESTINAL DISORDERS Nausea 7% NERVOUS SYSTEM DISORDERS Dizziness 3% Somnolence 3% * Hypotension resolved during esmolol hydrochloride infusion in 63% of patients. In 80% of the remaining patients, hypotension resolved within 30 minutes following discontinuation of infusion. Clinical Trial Adverse Reactions (Frequency <3%) Psychiatric Disorders Confusional state and agitation (~2%) Anxiety, depression and abnormal thinking (<1%) Nervous System Disorders Headache (~ 2%) Paresthesia, syncope, speech disorder, and lightheadedness (<1%) Convulsions (<1%), with one death Vascular Disorders Peripheral ischemia (~1%) Pallor and flushing (<1%) Gastrointestinal Disorders Vomiting (~1%) Dyspepsia, constipation, dry mouth, and abdominal discomfort (<1%) Renal and Urinary Disorders Urinary retention (<1%) 6.2 Post-Marketing Experience In addition to the adverse reactions reported in clinical trials, the following adverse reactions have been reported in the post-marketing experience. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure. Cardiac Disorders Cardiac arrest, Coronary arteriospasm Skin and Subcutaneous Tissue Disorders Angioedema, Urticaria, Psoriasis"],"contraindications":["4 CONTRAINDICATIONS Esmolol hydrochloride injection is contraindicated in patients with: Severe sinus bradycardia: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions ( 5.2 )]. Heart block greater than first degree: Second- or third-degree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions ( 5.2 )]. Sick sinus syndrome: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions ( 5.2 )]. Decompensated heart failure: May worsen heart failure. Cardiogenic shock: May precipitate further cardiovascular collapse and cause cardiac arrest. IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and esmolol hydrochloride injection in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving esmolol hydrochloride injection and intravenous verapamil. Pulmonary hypertension: May precipitate cardiorespiratory compromise. Hypersensitivity reactions, including anaphylaxis, to esmolol or any of the inactive ingredients of the product (cross-sensitivity between beta blockers is possible). Severe sinus bradycardia ( 4 ) Heart block greater than first degree ( 4 ) Sick sinus syndrome ( 4 ) Decompensated heart failure ( 4 ) Cardiogenic shock ( 4 ) Coadministration of IV cardiodepressant calcium-channel antagonists (e.g. verapamil) in close proximity to esmolol hydrochloride injection ( 4 , 7 ) Pulmonary hypertension ( 4 ) Known hypersensitivity to esmolol ( 4 )"],"description_table":["
Esmolol Hydrochloride, USP 10 mg/mL
Sodium Chloride, USP 5.9 mg/mL
Water for Injection, USP Q.S. to volume of 10 mL
Sodium Acetate Trihydrate, USP 2.8 mg/mL
Glacial Acetic Acid, USP 0.546 mg/mL
Sodium Hydroxide Q.S. to adjust pH to 4.5 to 5.5
Hydrochloric Acid Q.S. to adjust pH to 4.5 to 5.5
Q.S. = Quantity sufficient
"],"drug_interactions":["7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride injection’s effects on blood pressure, contractility, and impulse propagation. Severe interactions with such drugs can result in, for example, severe hypotension, cardiac failure, severe bradycardia, sinus pause, sinoatrial block, atrioventricular block, and/or cardiac arrest. In addition, with some drugs, beta blockade may precipitate increased withdrawal effects. (See clonidine, guanfacine, and moxonidine below.) Esmolol hydrochloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride injection leads to an approximate 10% to 20% increase of digoxin blood levels at some time points. Digoxin does not affect esmolol hydrochloride injection pharmacokinetics. Both digoxin and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use increases the risk of bradycardia. Anticholinesterases: Esmolol hydrochloride injection prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium. Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. If, during concomitant use of a beta blocker, antihypertensive therapy needs to be interrupted or discontinued, discontinue the beta blocker first, and the discontinuation should be gradual. Calcium channel antagonists: In patients with depressed myocardial function, use of esmolol hydrochloride injection with cardiodepressant calcium channel antagonists (e.g., verapamil) can lead to fatal cardiac arrests. Sympathomimetic drugs: Sympathomimetic drugs having beta-adrenergic agonist activity will counteract effects of esmolol hydrochloride injection. Vasoconstrictive and positive inotropic agents: Because of the risk of reducing cardiac contractility in presence of high systemic vascular resistance, do not use esmolol hydrochloride injection to control tachycardia in patients receiving drugs that are vasoconstrictive and have positive inotropic effects, such as epinephrine, norepinephrine, and dopamine. Digitalis glycosides: Risk of bradycardia ( 7 ) Anticholinesterases: Prolongs neuromuscular blockade ( 7 ) Antihypertensive agents: Risk of rebound hypertension ( 7 ) Sympathomimetic drugs: Dose adjustment needed ( 7 ) Vasoconstrictive and positive inotropic effect substances: Avoid concomitant use ( 7 )"],"how_supplied_table":["
NDC 68083-211-25 Esmolol hydrochloride injection 100 mg/10 mL (10 mg/mL) 10 mL single dose vial Package Factor 25 vials per carton
"],"labor_and_delivery":["8.2 Labor and Delivery Although there are no adequate and well-controlled studies in pregnant women, use of esmolol in the last trimester of pregnancy or during labor or delivery has been reported to cause fetal bradycardia, which continued after termination of drug infusion. Esmolol hydrochloride injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"mechanism_of_action":["12.1 Mechanism of Action Esmolol hydrochloride injection is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately 9 minutes. Esmolol hydrochloride injection inhibits the beta 1 receptors located chiefly in cardiac muscle, but this preferential effect is not absolute and at higher doses it begins to inhibit beta 2 receptors located chiefly in the bronchial and vascular musculature."],"recent_major_changes":["Warnings and Precautions, Hypoglycemia ( 5.6 ) 06/2023"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Esmolol hydrochloride injection is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately 9 minutes. Esmolol hydrochloride injection inhibits the beta 1 receptors located chiefly in cardiac muscle, but this preferential effect is not absolute and at higher doses it begins to inhibit beta 2 receptors located chiefly in the bronchial and vascular musculature. 12.2 Pharmacodynamics Clinical pharmacology studies in normal volunteers have confirmed the beta blocking activity of esmolol hydrochloride injection, showing reduction in heart rate at rest and during exercise, and attenuation of isoproterenol-induced increases in heart rate. Blood levels of esmolol hydrochloride injection have been shown to correlate with extent of beta blockade. After termination of infusion, substantial recovery from beta blockade is observed in 10 to 20 minutes. The acid metabolite of esmolol exhibits negligible pharmacological activity. In human electrophysiology studies, esmolol hydrochloride injection produced effects typical of a beta blocker: a decrease in the heart rate, increase in sinus cycle length, prolongation of the sinus node recovery time, prolongation of the AH interval during normal sinus rhythm and during atrial pacing, and an increase in antegrade Wenckebach cycle length. In patients undergoing radionuclide angiography, esmolol hydrochloride injection, at dosages of 200 mcg/kg/min, produced reductions in heart rate, systolic blood pressure, rate pressure product, left and right ventricular ejection fraction and cardiac index at rest, which were similar in magnitude to those produced by intravenous propranolol (4 mg). During exercise, esmolol hydrochloride injection produced reductions in heart rate, rate pressure product and cardiac index which were also similar to those produced by propranolol, but esmolol hydrochloride produced a significantly larger fall in systolic blood pressure. In patients undergoing cardiac catheterization, the maximum therapeutic dose of 300 mcg/kg/min of esmolol hydrochloride injection produced similar effects and, in addition, there were small, clinically insignificant increases in the left ventricular end diastolic pressure and pulmonary capillary wedge pressure. At 30 minutes after the discontinuation of esmolol hydrochloride infusion, all of the hemodynamic parameters had returned to pretreatment levels. The relative cardioselectivity of esmolol hydrochloride injection was demonstrated in 10 mildly asthmatic patients. Infusions of esmolol hydrochloride injection 100, 200 and 300 mcg/kg/min produced no significant increases in specific airway resistance compared to placebo. At 300 mcg/kg/min, esmolol hydrochloride injection produced slightly enhanced bronchomotor sensitivity to dry air stimulus. These effects were not clinically significant, and esmolol hydrochloride injection was well tolerated by all patients. Six of the patients also received intravenous propranolol, and at a dosage of 1 mg, two experienced significant, symptomatic bronchospasm requiring bronchodilator treatment. One other propranolol-treated patient also experienced dry air-induced bronchospasm. No adverse pulmonary effects were observed in patients with COPD who received therapeutic dosages of esmolol hydrochloride injection for treatment of supraventricular tachycardia (51 patients) or in perioperative settings (32 patients). 12.3 Pharmacokinetics Esmolol is rapidly metabolized by hydrolysis of the ester linkage, chiefly by the esterases in the cytosol of red blood cells and not by plasma cholinesterases or red cell membrane acetylcholinesterase. Total body clearance in man was found to be about 20 L/kg/hr, which is greater than cardiac output; thus the metabolism of esmolol is not limited by the rate of blood flow to metabolizing tissues such as the liver or affected by hepatic or renal blood flow. Esmolol has a rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes. Using an appropriate loading dose, steady-state blood levels of esmolol hydrochloride injection for dosages from 50 to 300 mcg/kg/min are obtained within five minutes. Steady-state is reached in about 30 minutes without the loading dose. Steady-state blood levels of esmolol increase linearly over this dosage range and elimination kinetics are dose-independent over this range. Steady-state blood levels are maintained during infusion but decrease rapidly after termination of the infusion. Because of its short half-life, blood levels of esmolol can be rapidly altered by increasing or decreasing the infusion rate and rapidly eliminated by discontinuing the infusion. Consistent with the high rate of blood-based metabolism of esmolol, less than 2% of the drug is excreted unchanged in the urine. Within 24 hours of the end of infusion, the acid metabolite of esmolol in urine accounts for approximately 73 to 88% of the dosage. Metabolism of esmolol results in the formation of the corresponding free acid and methanol. The acid metabolite has been shown in animals to have negligible activity and in normal volunteers its blood levels do not correspond to the level of beta blockade. The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate. After a 4 hour maintenance infusion of 150 mcg/kg, the plasma concentrations of esmolol are similar in subjects with normal renal function and in patients with ESRD on dialysis. The half-life of the acid metabolite of esmolol hydrochloride injection, which is primarily excreted unchanged by the kidney, is increased about 12-fold to 48 hours in patients with ESRD. The peak concentrations of the acid metabolite are doubled in ESRD. Methanol blood levels, monitored in subjects receiving esmolol hydrochloride injection for up to 6 hours at 300 mcg/kg/min and 24 hours at 150 mcg/kg/min, approximated endogenous levels and were less than 2% of levels usually associated with methanol toxicity. Esmolol hydrochloride injection has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound."],"indications_and_usage":["1 INDICATIONS AND USAGE Esmolol hydrochloride injection is a beta adrenergic blocker indicated for the short-term treatment of: Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia ( 1.1 ) Control of perioperative tachycardia and hypertension ( 1.2 ) 1.1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia Esmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride injection is intended for short-term use. 1.2 Intraoperative and Postoperative Tachycardia and/or Hypertension Esmolol hydrochloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. Use of esmolol hydrochloride injection to prevent such events is not recommended."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Risk of hypotension, bradycardia, and cardiac failure: Monitor for signs and symptoms of cardiovascular adverse effects. Reduce or discontinue use ( 5.1 , 5.2 , 5.3 , 5.10 ) • Risk of exacerbating reactive airway disease ( 5.5 ) • Diabetes: May mask symptoms of hypoglycemia and alter glucose levels; monitor ( 5.6 ) • Risk of unopposed alpha-agonism and severe hypertension in untreated pheochromocytoma ( 5.9 ) • Risk of myocardial ischemia when abruptly discontinued in patients with coronary artery disease ( 5.12 , 5.15 ) 5.1 Hypotension Hypotension can occur at any dose but is dose-related. Patients with hemodynamic compromise or on interacting medications are at particular risk. Severe reactions may include loss of consciousness, cardiac arrest, and death. For control of ventricular heart rate, maintenance doses greater than 200 mcg per kg per min are not recommended. Monitor patients closely, especially if pretreatment blood pressure is low. In case of an unacceptable drop in blood pressure, reduce or stop esmolol hydrochloride injection. Decrease of dose or termination of infusion reverses hypotension, usually within 30 minutes. 5.2 Bradycardia Bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest have occurred with the use of esmolol hydrochloride injection. Patients with first-degree atrioventricular block, sinus node dysfunction, or conduction disorders may be at increased risk. Monitor heart rate and rhythm in patients receiving esmolol hydrochloride injection [see Contraindications ( 4 )]. If severe bradycardia develops, reduce or stop esmolol hydrochloride injection. 5.3 Cardiac Failure Beta blockers, like esmolol hydrochloride injection, can cause depression of myocardial contractility and may precipitate heart failure and cardiogenic shock. At the first sign or symptom of impending cardiac failure, stop esmolol hydrochloride injection and start supportive therapy [see Overdosage ( 10 )]. 5.4 Intraoperative and Postoperative Tachycardia and/or Hypertension Monitor vital signs closely and titrate esmolol hydrochloride injection slowly in the treatment of patients whose blood pressure is primarily driven by vasoconstriction associated with hypothermia. 5.5 Reactive Airways Disease Patients with reactive airways disease should, in general, not receive beta blockers. Because of its relative beta 1 selectivity and titratability, titrate esmolol hydrochloride injection to the lowest possible effective dose. In the event of bronchospasm, stop the infusion immediately; a beta 2 stimulating agent may be administered with appropriate monitoring of ventricular rates. 5.6 Hypoglycemia Beta-blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at any time during treatment, especially in patients with diabetes mellitus or children and patients who are fasting (i.e., surgery, not eating regularly, or are vomiting). If severe hypoglycemia occurs, patients should be instructed to seek emergency treatment. 5.7 Infusion Site Reactions Infusion site reactions have occurred with the use of esmolol hydrochloride injection. They include irritation, inflammation, and severe reactions (thrombophlebitis, necrosis, and blistering), in particular when associated with extravasation [see Adverse Reactions ( 6 )]. Avoid infusions into small veins or through a butterfly catheter. If a local infusion site reaction develops, use an alternative infusion site and avoid extravasation. 5.8 Use in Patients with Prinzmetal's Angina Beta blockers may exacerbate anginal attacks in patients with Prinzmetal's angina because of unopposed alpha receptor-mediated coronary artery vasoconstriction. Do not use nonselective beta blockers. 5.9 Use in Patients with Pheochromocytoma If esmolol hydrochloride injection is used in the setting of pheochromocytoma, give it in combination with an alpha-blocker, and only after the alpha-blocker has been initiated. Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure from the attenuation of beta-mediated vasodilation in skeletal muscle. 5.10 Use in Hypovolemic Patients In hypovolemic patients, esmolol hydrochloride injection can attenuate reflex tachycardia and increase the risk of hypotension. 5.11 Use in Patients with Peripheral Circulatory Disorders In patients with peripheral circulatory disorders (including Raynaud's disease or syndrome, and peripheral occlusive vascular disease), esmolol hydrochloride injection may aggravate peripheral circulatory disorders. 5.12 Abrupt Discontinuation of Esmolol Hydrochloride Injection Severe exacerbations of angina, myocardial infarction, and ventricular arrhythmias have been reported in patients with coronary artery disease upon abrupt discontinuation of beta blocker therapy. Observe patients for signs of myocardial ischemia when discontinuing esmolol hydrochloride injection. Heart rate increases moderately above pretreatment levels 30 minutes after esmolol hydrochloride injection discontinuation. 5.13 Hyperkalemia Beta blockers, including esmolol hydrochloride injection, have been associated with increases in serum potassium levels and hyperkalemia. The risk is increased in patients with risk factors such as renal impairment. Intravenous administration of beta blockers has been reported to cause potentially life-threatening hyperkalemia in hemodialysis patients. Monitor serum electrolytes during therapy with esmolol hydrochloride injection. 5.14 Use in Patients with Metabolic Acidosis Beta blockers, including esmolol hydrochloride injection, have been reported to cause hyperkalemic renal tubular acidosis. Acidosis in general may be associated with reduced cardiac contractility. 5.15 Use in Patients with Hyperthyroidism Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, monitor patients for signs of thyrotoxicosis when withdrawing beta blocking therapy. 5.16 Use in Patients at Risk of Severe Acute Hypersensitivity Reactions When using beta blockers, patients at risk of anaphylactic reactions may be more reactive to allergen exposure (accidental, diagnostic, or therapeutic). Patients using beta blockers may be unresponsive to the usual doses of epinephrine used to treat anaphylactic or anaphylactoid reactions [see Drug Interactions ( 7 )]."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY Because of its short term usage no carcinogenicity, mutagenicity, or reproductive performance studies have been conducted with esmolol."],"adverse_reactions_table":["
System Organ Class (SOC) Preferred MedDRA Term Frequency
VASCULAR DISORDERS Hypotension* Asymptomatic hypotension Symptomatic hypotension (hyperhidrosis, dizziness) 25% 12%
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Infusion site reactions (inflammation and induration)8%
GASTROINTESTINAL DISORDERS Nausea7%
NERVOUS SYSTEM DISORDERS Dizziness3%
Somnolence3%
* Hypotension resolved during esmolol hydrochloride infusion in 63% of patients. In 80% of the remaining patients, hypotension resolved within 30 minutes following discontinuation of infusion.
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Physicians should inform patients of the risks associated with esmolol hydrochloride injection: The most common adverse reactions are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension. Inform patients or caregivers that there is a risk of hypoglycemia when esmolol is given to patients who are fasting or who are vomiting. Monitor for symptoms of hypoglycemia. [See Warnings and Precautions ( 5.6) ] . Manufactured by: Gland Pharma Limited D.P.Pally, Dundigal Post Hyderabad-500043, India Revised: 07/2023"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • Administer intravenously ( 2.1 , 2.2 ) • Titrate using ventricular rate or blood pressure at ≥4-minute intervals. ( 2.1 , 2.2 ) • Supraventricular tachycardia (SVT) or noncompensatory sinus tachycardia ( 2.1 ) • Optional loading dose: 500 mcg per kg infused over one minute • Then 50 mcg per kg per minute for the next 4 minutes • Adjust dose as needed to a maximum of 200 mcg per kg per minute. • Additional loading doses may be administered • Perioperative tachycardia and hypertension ( 2.2 ) • Loading dose: 500 mcg per kg over 1 minute for gradual control (1 mg per kg over 30 seconds for immediate control) • Then 50 mcg per kg per min for gradual control (150 mcg per kg per minute for immediate control) adjusted to a maximum of 200 (tachycardia) or 300 (hypertension) mcg per kg per min ( 2.2 ) 2.1 Dosing for the Treatment of Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia Esmolol hydrochloride injection is administered by continuous intravenous infusion with or without a loading dose. Additional loading doses and/or titration of the maintenance infusion (step-wise dosing) may be necessary based on desired ventricular response. Table 1 Step-Wise Dosing Step Action 1 Optional loading dose (500 mcg per kg over 1 minute),then 50 mcg per kg per min for 4 min 2 Optional loading dose if necessary, then 100 mcg per kg per min for 4 min 3 Optional loading dose if necessary, then 150 mcg per kg per min for 4 min 4 If necessary, increase dose to 200 mcg per kg per min In the absence of loading doses, continuous infusion of a single concentration of esmolol reaches pharmacokinetic and pharmacodynamic steady-state in about 30 minutes. The effective maintenance dose for continuous and step-wise dosing is 50 to 200 mcg per kg per minute, although doses as low as 25 mcg per kg per minute have been adequate. Dosages greater than 200 mcg per kg per minute provide little added heart rate lowering effect, and the rate of adverse reactions increases. Maintenance infusions may be continued for up to 48 hours. 2.2 Intraoperative and Postoperative Tachycardia and Hypertension In this setting it is not always advisable to slowly titrate to a therapeutic effect. Therefore two dosing options are presented: immediate control and gradual control. Immediate Control Administer 1 mg per kg as a bolus dose over 30 seconds followed by an infusion of 150 mcg per kg per min if necessary. Adjust the infusion rate as required to maintain desired heart rate and blood pressure. Refer to Maximum Recommended Doses below. Gradual Control Administer 500 mcg per kg as a bolus dose over 1 minute followed by a maintenance infusion of 50 mcg per kg per min for 4 minutes. Depending on the response obtained, continue dosing as outlined for supraventricular tachycardia. Refer to Maximum Recommended Doses below. Maximum Recommended Doses For the treatment of tachycardia, maintenance infusion dosages greater than 200 mcg per kg per min are not recommended; dosages greater than 200 mcg per kg per min provide little additional heart rate-lowering effect, and the rate of adverse reactions increases. For the treatment of hypertension, higher maintenance infusion dosages (250 to 300 mcg per kg per min) may be required. The safety of doses above 300 mcg per kg per minute has not been studied. 2.3 Transition from Esmolol Hydrochloride Injection Therapy to Alternative Drugs After patients achieve adequate control of the heart rate and a stable clinical status, transition to alternative antiarrhythmic drugs may be accomplished. When transitioning from esmolol hydrochloride injection to alternative drugs, the physician should carefully consider the labeling instructions of the alternative drug selected and reduce the dosage of esmolol hydrochloride injection as follows: Thirty minutes following the first dose of the alternative drug, reduce the esmolol hydrochloride infusion rate by one-half (50%). After administration of the second dose of the alternative drug, monitor the patient's response and if satisfactory control is maintained for the first hour, discontinue the esmolol hydrochloride infusion. 2.4 Directions for Use Esmolol hydrochloride injection is available in a ready-to-use vial. Esmolol hydrochloride injection is not compatible with Sodium Bicarbonate (5%) solution (limited stability) or furosemide (precipitation). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Ready-to-Use Vial The Ready-to-use Vial may be used to administer a loading dosage by hand-held syringe while the maintenance infusion is being prepared [see How Supplied/Storage and Handling ( 16.2 )]. Compatibility with Commonly Used Intravenous Fluids Esmolol hydrochloride injection was tested for compatibility with ten commonly used intravenous fluids at a final concentration of 10 mg esmolol hydrochloride per mL. Esmolol hydrochloride injection was found to be compatible with the following solutions and was stable for at least 24 hours at controlled room temperature or under refrigeration: Dextrose (5%) Injection, USP Dextrose (5%) in Lactated Ringer's Injection Dextrose (5%) in Ringer's Injection Dextrose (5%) and Sodium Chloride (0.45%) Injection, USP Dextrose (5%) and Sodium Chloride (0.9%) Injection, USP Lactated Ringer's Injection, USP Potassium Chloride (40 mEq/liter) in Dextrose (5%) Injection, USP Sodium Chloride (0.45%) Injection, USP Sodium Chloride (0.9%) Injection, USP"],"spl_product_data_elements":["Esmolol Hydrochloride Esmolol Hydrochloride ESMOLOL HYDROCHLORIDE ESMOLOL SODIUM ACETATE SODIUM CHLORIDE ACETIC ACID WATER SODIUM HYDROXIDE HYDROCHLORIC ACID"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Esmolol hydrochloride injection is an iso-osmotic solution of esmolol hydrochloride in sodium chloride. Table 2 Esmolol Hydrochloride Injection Presentation Product Name Esmolol Hydrochloride Injection Total Dose 100 mg/10 mL Esmolol Hydrochloride Concentration 10 mg/mL Packaging 10 mL Vial Injection: 100 mg/10 mL (10 mg/mL) in 10 mL vial ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Esmolol hydrochloride has been shown to produce increased fetal resorptions with minimal maternal toxicity in rabbits when given in doses approximately 8 times the maximum human maintenance dose (300 mcg/kg/min). There are no adequate and well-controlled studies in pregnant women. Esmolol hydrochloride injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Teratogenicity studies in rats at intravenous dosages of esmolol hydrochloride up to 3000 mcg/kg/min (10 times the maximum human maintenance dosage) for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while a dosage of 10,000 mcg/kg/min produced maternal toxicity and lethality. In rabbits, intravenous dosages up to 1000 mcg/kg/min for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while 2500 mcg/kg/min produced minimal maternal toxicity and increased fetal resorptions. 8.2 Labor and Delivery Although there are no adequate and well-controlled studies in pregnant women, use of esmolol in the last trimester of pregnancy or during labor or delivery has been reported to cause fetal bradycardia, which continued after termination of drug infusion. Esmolol hydrochloride injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. 8.3 Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from esmolol hydrochloride injection, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. 8.4 Pediatric Use The safety and effectiveness of esmolol hydrochloride injection in pediatric patients have not been established. 8.5 Geriatric Use Clinical studies of esmolol hydrochloride injection did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should usually start at the low end of the dosing range, reflecting greater frequency of decreased renal or cardiac function and of concomitant disease or other drug therapy. 8.6 Hepatic Impairment No special precautions are necessary in patients with hepatic impairment because esmolol hydrochloride injection is metabolized by red-blood cell esterases [see Clinical Pharmacology ( 12 )]. 8.7 Renal Impairment No dosage adjustment is required for esmolol in patients with renal impairment receiving a maintenance infusion of esmolol 150 mcg/kg for 4 hours. There is no information on the tolerability of maintenance infusions of esmolol using rates in excess of 150 mcg/kg or maintained longer than 4 hours [see Clinical Pharmacology ( 12 )]."],"dosage_and_administration_table":["
Step Action
1 Optional loading dose (500 mcg per kg over 1 minute),then 50 mcg per kg per min for 4 min
2 Optional loading dose if necessary, then 100 mcg per kg per min for 4 min
3 Optional loading dose if necessary, then 150 mcg per kg per min for 4 min
4 If necessary, increase dose to 200 mcg per kg per min
"],"dosage_forms_and_strengths_table":["
Product Name Esmolol Hydrochloride Injection
Total Dose 100 mg/10 mL
Esmolol Hydrochloride Concentration 10 mg/mL
Packaging 10 mL Vial
"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 68083-211-01 Esmolol Hydrochloride Injection 100 mg/10 mL (10 mg/mL) For Intravenous Use Iso-Osmotic Contains no preservatives – discard unused portion 10 mL single dose vial NDC 68083-211-25 Esmolol Hydrochloride Injection 100 mg/10 mL (10 mg/mL) For Intravenous Use Iso-Osmotic Contains no preservatives – discard unused portion 25 × 10 mL Single Dose Vials esmolol-spl-figure-1 esmolol-spl-Figure-2"]},"tags":[{"label":"beta-Adrenergic Blocker","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Beta-1 adrenergic receptor","category":"target"},{"label":"ADRB1","category":"gene"},{"label":"C07AB09","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Atrial fibrillation","category":"indication"},{"label":"Perioperative Tachycardia","category":"indication"},{"label":"Perioperative hypertension","category":"indication"},{"label":"Supraventricular tachycardia","category":"indication"},{"label":"Hq Spclt Pharma","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Antagonists","category":"pharmacology"},{"label":"Adrenergic beta-1 Receptor Antagonists","category":"pharmacology"},{"label":"Adrenergic beta-Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"CARDIAC ARREST","source":"FDA FAERS","actionTaken":"21 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"19 reports"},{"date":"","signal":"BRADYCARDIA","source":"FDA FAERS","actionTaken":"17 reports"},{"date":"","signal":"PRODUCT USE ISSUE","source":"FDA FAERS","actionTaken":"15 reports"},{"date":"","signal":"PRODUCT USE IN UNAPPROVED INDICATION","source":"FDA FAERS","actionTaken":"12 reports"},{"date":"","signal":"RENAL FAILURE","source":"FDA FAERS","actionTaken":"11 reports"},{"date":"","signal":"ATRIAL FIBRILLATION","source":"FDA FAERS","actionTaken":"9 reports"},{"date":"","signal":"HYPERTENSION","source":"FDA FAERS","actionTaken":"9 reports"},{"date":"","signal":"VENTRICULAR FIBRILLATION","source":"FDA FAERS","actionTaken":"9 reports"}],"drugInteractions":[{"url":"/drug/felodipine","drug":"felodipine","action":"Monitor closely","effect":"May interact with Felodipine","source":"DrugCentral","drugSlug":"felodipine"}],"commonSideEffects":[{"effect":"Dizziness","drugRate":"3%","severity":"common","_validated":true},{"effect":"Somnolence","drugRate":"3%","severity":"common","_validated":true},{"effect":"Nausea","drugRate":"7%","severity":"common","_validated":true},{"effect":"Infusion site reactions","drugRate":"8%","severity":"common","_validated":true},{"effect":"Confusion","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Headache","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Agitation","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Fatigue","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Vomiting","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Seizures","drugRate":"reported","severity":"unknown"},{"effect":"Paresthesia","drugRate":"reported","severity":"unknown"},{"effect":"Asthenia","drugRate":"reported","severity":"unknown"},{"effect":"Depression","drugRate":"reported","severity":"unknown"},{"effect":"Abnormal thinking","drugRate":"reported","severity":"unknown"},{"effect":"Anxiety","drugRate":"reported","severity":"unknown"},{"effect":"Anorexia","drugRate":"reported","severity":"unknown"},{"effect":"Lightheadedness","drugRate":"reported","severity":"unknown"},{"effect":"Bronchospasm","drugRate":"reported","severity":"unknown"},{"effect":"Wheezing","drugRate":"reported","severity":"unknown"},{"effect":"Dyspnea","drugRate":"reported","severity":"unknown"},{"effect":"Nasal congestion","drugRate":"reported","severity":"unknown"},{"effect":"Rhonchi","drugRate":"reported","severity":"unknown"},{"effect":"Rales","drugRate":"reported","severity":"unknown"},{"effect":"Dyspepsia","drugRate":"reported","severity":"unknown"},{"effect":"Constipation","drugRate":"reported","severity":"unknown"},{"effect":"Dry mouth","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal discomfort","drugRate":"reported","severity":"unknown"},{"effect":"Taste perversion","drugRate":"reported","severity":"unknown"},{"effect":"Edema","drugRate":"reported","severity":"unknown"},{"effect":"Erythema","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute exacerbation of asthma","Anaphylaxis","Bronchospasm","Cardiogenic shock","Decompensated cardiac failure","Diabetes mellitus","Heart block","Kidney disease","Pulmonary emphysema","Sinus bradycardia"],"specialPopulations":{"Pregnancy":"Esmolol hydrochloride has been shown to produce increased fetal resorptions with minimal maternal toxicity in rabbits when given in doses approximately times the maximum human maintenance dose (300 mcg/kg/min). There are no adequate and well-controlled studies in pregnant women. Esmolol hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Teratogenicity studies in rats at intravenous dosages of esmolol hydrochloride up to 3000 mcg/kg/min (10 times the maximum human maintenance dosage) for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while dosage of 10,000 mcg/kg/min produced maternal toxicity and lethality. In rabbits, intravenous dosages up to 1000 mcg/kg/min for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while 2500 mcg/kg/min produced minimal maternal toxicity and increased fetal resorptions. Although there are no adequate and well-controlled studies in pregnant women, use of esmolol in the last trimester of pregnancy or during labor or delivery has been reported to cause fetal bradycardia, which continued after termination of drug infusion. Esmolol hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","Geriatric use":"Clinical studies of esmolol hydrochloride injection did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should usually start at the low end of the dosing range, reflecting greater frequency of decreased renal or cardiac function.","Paediatric use":"Teratogenicity studies in rats at intravenous dosages of esmolol hydrochloride up to 3000 mcg/kg/min (3 mg/kg/min) (ten times the maximum human maintenance dosage) for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while dosage of 10,000 mcg/kg/min produced maternal toxicity and lethality. In rabbits, intravenous dosages up to 1000 mcg/kg/min for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while dosage of 2500 mcg/kg/min produced minimal maternal toxicity and increased fetal resorptions. Pregnancy Category C."}},"trials":[],"aliases":[],"company":"Pfizer","patents":[{"applNo":"N205703","source":"FDA Orange Book","status":"Active","expires":"Mar 15, 2033","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8829054","drugSubstance":false},{"applNo":"N205703","source":"FDA Orange Book","status":"Active","expires":"Mar 15, 2033","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8835505","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ESMOLOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:50:33.326762+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:50:33.326337+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:51:18.215164+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:50:39.822206+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:50:31.917966+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ESMOLOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:50:40.656026+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:50:30.174125+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:51:11.498329+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:50:30.174187+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:50:42.154962+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Beta-2 adrenergic receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:50:41.221120+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201115/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:50:41.117713+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA208538","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:50:30.174194+00:00"}},"allNames":"brevibloc in plastic container","offLabel":[],"synonyms":["esmolol","brevibloc","esmolol hydrochloride","esmolol HCl"],"timeline":[{"date":"1986-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from BAXTER HLTHCARE to Hq Spclt Pharma"},{"date":"1986-12-31","type":"positive","source":"DrugCentral","milestone":"FDA approval (Baxter Hlthcare)"},{"date":"1988-08-15","type":"positive","source":"FDA Orange Book","milestone":"Brevibloc approved — 10MG/ML"},{"date":"2004-08-10","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"aiSummary":"ESMOLol (Brevibloc In Plastic Container), marketed by Pfizer, is a beta-1 adrenergic receptor blocker primarily indicated for controlling ventricular rate in supraventricular tachycardia. Its key strength lies in its targeted mechanism of action, which effectively reduces the heart's response to stress and increases heart rate, setting it apart in the treatment of acute cardiac conditions. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generics.","approvals":[{"date":"1986-12-31","orphan":false,"company":"BAXTER HLTHCARE","regulator":"FDA"}],"brandName":"Brevibloc In Plastic Container","ecosystem":[{"indication":"Atrial fibrillation","otherDrugs":[{"name":"acetyldigitoxin","slug":"acetyldigitoxin","company":"Novartis"},{"name":"bisoprolol","slug":"bisoprolol","company":"Teva Womens"},{"name":"clopidogrel","slug":"clopidogrel","company":"Sanofi Aventis Us"},{"name":"digoxin","slug":"digoxin","company":"Eurohlth Intl Sarl"}],"globalPrevalence":59000000},{"indication":"Perioperative Tachycardia","otherDrugs":[],"globalPrevalence":null},{"indication":"Perioperative hypertension","otherDrugs":[{"name":"glyceryl trinitrate","slug":"glyceryl-trinitrate","company":"Fougera"}],"globalPrevalence":1280000000},{"indication":"Supraventricular tachycardia","otherDrugs":[{"name":"propranolol","slug":"propranolol","company":"Baxter Hlthcare Corp"}],"globalPrevalence":null}],"mechanism":{"target":"Beta-1 adrenergic receptor","novelty":"Follow-on","targets":[{"gene":"ADRB1","source":"DrugCentral","target":"Beta-1 adrenergic receptor","protein":"Beta-1 adrenergic receptor"}],"moaClass":"Adrenergic beta-Antagonists","modality":"Small Molecule","drugClass":"beta-Adrenergic Blocker","explanation":"Esmolol hydrochloride is beta1-selective (cardioselective) adrenergic receptor blocking agent with rapid onset, very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately minutes. Esmolol hydrochloride inhibits the beta1 receptors located chiefly in cardiac muscle, but this preferential effect is not absolute and at higher doses it begins to inhibit beta2 receptors located chiefly in the bronchial and vascular musculature.","oneSentence":"Brevibloc works by blocking the beta-1 adrenergic receptor, which reduces the heart's response to stress and increases heart rate.","technicalDetail":"Brevibloc is a selective beta-1 adrenergic receptor antagonist that competitively inhibits the effects of endogenous catecholamines, such as epinephrine and norepinephrine, resulting in decreased heart rate, contractility, and cardiac output."},"commercial":{"launchDate":"1986","_launchSource":"DrugCentral (FDA 1986-12-31, BAXTER HLTHCARE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1054","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ESMOLOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ESMOLOL","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:02:49.212976","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:51:18.215831+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"metoprolol","drugSlug":"metoprolol","fdaApproval":"1978-08-07","patentExpiry":"Jul 9, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"atenolol","drugSlug":"atenolol","fdaApproval":"1981-08-19","genericCount":22,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acebutolol","drugSlug":"acebutolol","fdaApproval":"1984-12-28","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"betaxolol","drugSlug":"betaxolol","fdaApproval":"1985-08-30","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"bisoprolol","drugSlug":"bisoprolol","fdaApproval":"1992-07-31","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nebivolol","drugSlug":"nebivolol","fdaApproval":"2007-12-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"esmolol","indications":{"approved":[{"id":"esmolol-control-of-ventricular-rate-in","name":"Control of ventricular rate in supraventricular tachycardia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances","diagnosticRequired":null,"brandNameForIndication":"Brevibloc In Plastic Container"},{"id":"esmolol-control-of-heart-rate-in-nonco","name":"Control of heart rate in noncompensatory sinus tachycardia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with noncompensatory sinus tachycardia requiring specific intervention","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with noncompensatory sinus tachycardia requiring specific intervention","diagnosticRequired":null,"brandNameForIndication":"Brevibloc In Plastic Container"},{"id":"esmolol-control-of-perioperative-tachy","name":"Control of perioperative tachycardia and hypertension","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients experiencing tachycardia and hypertension during or after surgical procedures","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients experiencing tachycardia and hypertension during or after surgical procedures","diagnosticRequired":null,"brandNameForIndication":"Brevibloc In Plastic Container"}],"offLabel":[{"name":"Acute coronary syndrome","source":"DrugCentral","drugName":"ESMOLOL","evidenceCount":9,"evidenceLevel":"emerging"},{"name":"Dissection of aorta","source":"DrugCentral","drugName":"ESMOLOL","evidenceCount":27,"evidenceLevel":"moderate"},{"name":"Hypertensive urgency","source":"DrugCentral","drugName":"ESMOLOL","evidenceCount":24,"evidenceLevel":"moderate"},{"name":"Malignant essential hypertension","source":"DrugCentral","drugName":"ESMOLOL","evidenceCount":2,"evidenceLevel":"emerging"},{"name":"Prevention of Hypertension in Pheochromocytoma","source":"DrugCentral","drugName":"ESMOLOL","evidenceCount":10,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Hq Spclt Pharma","drugCategory":"established","labelChanges":[],"relatedDrugs":[{"drugId":"metoprolol","brandName":"metoprolol","genericName":"metoprolol","approvalYear":"1978","relationship":"same-class"},{"drugId":"atenolol","brandName":"atenolol","genericName":"atenolol","approvalYear":"1981","relationship":"same-class"},{"drugId":"acebutolol","brandName":"acebutolol","genericName":"acebutolol","approvalYear":"1984","relationship":"same-class"},{"drugId":"betaxolol","brandName":"betaxolol","genericName":"betaxolol","approvalYear":"1985","relationship":"same-class"},{"drugId":"bisoprolol","brandName":"bisoprolol","genericName":"bisoprolol","approvalYear":"1992","relationship":"same-class"},{"drugId":"nebivolol","brandName":"nebivolol","genericName":"nebivolol","approvalYear":"2007","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07489001","phase":"","title":"Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-12-09","conditions":["Lumbar Spinal Stenosis","Lumbar Disc Herniation With Radiculopathy","Lumbar Degenerative Spondylolisthesis","Lumbar Disc Degeneration"],"enrollment":75,"completionDate":"2026-12-10"},{"nctId":"NCT07313605","phase":"PHASE1,PHASE2","title":"POCUS-Guided Esmolol in Septic Shock: A Pilot RCT","status":"NOT_YET_RECRUITING","sponsor":"John Basmaji","startDate":"2026-01-15","conditions":["Septic Shock"],"enrollment":100,"completionDate":"2028-04-15"},{"nctId":"NCT07004686","phase":"NA","title":"Effect of MGRNOX-Guided General Anesthesia on Opioid Consumption in Patients","status":"RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-06-28","conditions":["Opioid Use"],"enrollment":112,"completionDate":"2026-05-30"},{"nctId":"NCT07019818","phase":"PHASE4","title":"Esmolol Versus Sufentanil on the Quality of Post-cholecystectomy Recovery Laparoscopic Anaesthesia With Orotracheal Intubation on an Outpatient Basis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2025-11-02","conditions":["Laparoscopic Cholecystectomy Surgery"],"enrollment":120,"completionDate":"2028-01-05"},{"nctId":"NCT06863558","phase":"PHASE3","title":"Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Intracerebral Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-05-08","conditions":["Intracerebral Hemorrhage"],"enrollment":58,"completionDate":"2026-06-30"},{"nctId":"NCT04181606","phase":"EARLY_PHASE1","title":"Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion","status":"COMPLETED","sponsor":"David N. Proctor, PhD","startDate":"2022-02-02","conditions":["Aging"],"enrollment":30,"completionDate":"2023-04-25"},{"nctId":"NCT06683911","phase":"","title":"Opioids Continue to Play a Primary Role in the Management of Perioperative Pain Due to Opioid-Free Anesthesia in Open Heart Surgery.","status":"COMPLETED","sponsor":"Ankara City Hospital Bilkent","startDate":"2024-04-03","conditions":["Undergoing Open-Heart Surgery"],"enrollment":98,"completionDate":"2025-04-03"},{"nctId":"NCT06958393","phase":"PHASE4","title":"Effect of Opioid-free Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery","status":"NOT_YET_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2025-05-20","conditions":["Delirium - Postoperative","Opioid-Free Anaesthesia"],"enrollment":406,"completionDate":"2026-05-12"},{"nctId":"NCT06863571","phase":"PHASE3","title":"Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-12","conditions":["Ischemic Stroke"],"enrollment":68,"completionDate":"2026-06-30"},{"nctId":"NCT06254534","phase":"NA","title":"Lidocaine, Dexmedetomidine, Esmolol and Magnesium Effect on Optic Nerve Sheath Diameter After Laryngoscopy","status":"RECRUITING","sponsor":"Haseki Training and Research Hospital","startDate":"2024-02-14","conditions":["Intracranial Hypertension","Endotracheal Intubation","Optic Nerve Sheath Diameter","General Anesthesia"],"enrollment":100,"completionDate":"2025-07"},{"nctId":"NCT02098629","phase":"PHASE2","title":"Concomitant Milrinone and Esmolol Treatment in Patients with Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Shantou University Medical College","startDate":"2015-05","conditions":["Myocardial Reperfusion Injury"],"enrollment":25,"completionDate":"2024-12"},{"nctId":"NCT04081545","phase":"PHASE3","title":"Effect of Opioid Free Anesthetic on Post-Operative Opioid Consumption After Laparoscopic Bariatric Surgery","status":"COMPLETED","sponsor":"Christine Oryhan","startDate":"2019-12-24","conditions":["Opioid Use, Unspecified","Bariatric Surgery Candidate","Anesthesia"],"enrollment":181,"completionDate":"2023-06-30"},{"nctId":"NCT06635707","phase":"","title":"Efficacy and Safety Study of Urapidil Alone or With Esmolol in Treating Acute Hypertensive Intracerebral Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2024-11-01","conditions":["Hypertensive Intracerebral Hemorrhage"],"enrollment":600,"completionDate":"2026-12-01"},{"nctId":"NCT06620991","phase":"NA","title":"Pre-operative Phentolamine Vs Intraoperative Esmolol Efficacy for Hypotensive Anesthesia in Functional Endoscopic Sinus Surgery","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-10-10","conditions":["Preoperative","Phentolamine","Intraoperative","Esmolol","Hypotensive Anesthesia","Functional Endoscopic Sinus Surgery"],"enrollment":60,"completionDate":"2025-04-01"},{"nctId":"NCT05769868","phase":"PHASE3","title":"Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments","status":"RECRUITING","sponsor":"Consorcio Centro de Investigación Biomédica en Red (CIBER)","startDate":"2023-04-18","conditions":["Cirrhosis","Diabetes Mellitus","Oncologic Disorders"],"enrollment":1000,"completionDate":"2027-09"},{"nctId":"NCT04356352","phase":"PHASE2,PHASE3","title":"Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2020-09-09","conditions":["Injection Site Irritation","Pain"],"enrollment":33,"completionDate":"2023-08-25"},{"nctId":"NCT06238973","phase":"NA","title":"Controlled Hypotension in Rhinoplasty and Septoplasty: Incidence of Cognitive Dysfunction and Delirium","status":"COMPLETED","sponsor":"Hitit University","startDate":"2024-02-06","conditions":["Hypotension During Surgery"],"enrollment":70,"completionDate":"2024-08-15"},{"nctId":"NCT06522594","phase":"PHASE2","title":"REMAP ECMO - Beta Receptor Modulation Trial","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2024-06-01","conditions":["Heart Failure","Cardiogenic Shock"],"enrollment":20,"completionDate":"2025-12-03"},{"nctId":"NCT06291363","phase":"PHASE4","title":"Impact of Administration of Esmolol on Nociception Level-guided Control of Nociception.","status":"RECRUITING","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2024-04-16","conditions":["Opioid Use, Unspecified","Anesthesia","Nociceptive Pain"],"enrollment":64,"completionDate":"2025-03-04"},{"nctId":"NCT06457100","phase":"PHASE1,PHASE2","title":"Esmolol Versus Lidocaine on the Quality of Postoperative Recovery in Patients Undergoing Functional Endoscopic Sinus Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Second People's Hospital of Huai'an","startDate":"2023-11-21","conditions":["Chronic Rhinosinusitis","Enhanced Recovery After Surgery"],"enrollment":60,"completionDate":"2024-06-22"},{"nctId":"NCT06390748","phase":"PHASE2","title":"Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes","status":"COMPLETED","sponsor":"Lin Chen","startDate":"2021-01-01","conditions":["Sepsis","Lymphocyte Disorder T","Immunologic Paralysis","Catecholamine; Overproduction","Beta-Blocker","Cytokine Storm","Sympathetic Nervous System Diseases"],"enrollment":150,"completionDate":"2023-12-31"},{"nctId":"NCT01113515","phase":"PHASE1,PHASE2","title":"Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Novalead Pharma Private Limited","startDate":"2014-02-20","conditions":["Diabetic Foot Ulcer"],"enrollment":44,"completionDate":"2015-10-17"},{"nctId":"NCT03549923","phase":"PHASE4","title":"Evaluation of Early CRRT InTerventions in Patients With ECMO(ELITE)","status":"COMPLETED","sponsor":"Beijing Anzhen Hospital","startDate":"2018-12-18","conditions":["Cardiogenic Shock"],"enrollment":131,"completionDate":"2023-05-01"},{"nctId":"NCT06376630","phase":"NA","title":"Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI","status":"RECRUITING","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2024-01-29","conditions":["Myocardial Infarction","Coronary Stenosis","Coronary Microvascular Dysfunction"],"enrollment":300,"completionDate":"2030-01-29"},{"nctId":"NCT06013319","phase":"PHASE3","title":"Effect of Esmolol on Oxygenation Index in Patients With Acute Respiratory Distress Syndrome","status":"RECRUITING","sponsor":"Zhiming Jiang","startDate":"2023-02-20","conditions":["Acute Respiratory Distress Syndrome"],"enrollment":178,"completionDate":"2026-10-30"},{"nctId":"NCT06268275","phase":"NA","title":"Comparison of Effects of Scalp Block and Intravenous Esmolol on Hemodynamic Response Following the Skull Pins Application for Elective Supratentorial Craniotomy","status":"COMPLETED","sponsor":"Khon Kaen University","startDate":"2022-09-19","conditions":["Hemodynamic Instability"],"enrollment":90,"completionDate":"2024-02-13"},{"nctId":"NCT06169475","phase":"NA","title":"Effect of Dexmedetomidine vs Esmolol or Placebo on Cerebral Hemodynamics in Septic Shock","status":"COMPLETED","sponsor":"Xinchen Wang","startDate":"2020-11-01","conditions":["Septic Shock","Stress Response","Cerebral Hemodynamics"],"enrollment":14,"completionDate":"2023-11-01"},{"nctId":"NCT05703048","phase":"NA","title":"The Effect of Esmolol Versus Dexmedetomidine on Postoperative Pain Control in Endoscopic Sinus Surgery: A Randomized Trial","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-12-30","conditions":["Patient's Satisfaction","Depth of Anesthesia"],"enrollment":70,"completionDate":"2024-06-30"},{"nctId":"NCT06065956","phase":"PHASE1,PHASE2","title":"Comparison of Hemodynamic Changes With Morphine Versus Esmolol During Induction of Anaesthesia","status":"COMPLETED","sponsor":"Pakistan Navy Station Shifa Hospital","startDate":"2022-08-28","conditions":["Intubation Complication"],"enrollment":110,"completionDate":"2023-07-15"},{"nctId":"NCT03998436","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Novalead Pharma Private Limited","startDate":"2018-12-26","conditions":["Diabetic Foot Ulcer"],"enrollment":176,"completionDate":"2021-12-06"},{"nctId":"NCT02120404","phase":"PHASE2","title":"Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-04","conditions":["Septic Shock"],"enrollment":45,"completionDate":"2023-10"},{"nctId":"NCT05950971","phase":"NA","title":"Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2021-07-01","conditions":["Atrial Fibrillation New Onset","Atrial Fibrillation Paroxysmal"],"enrollment":1,"completionDate":"2022-01-21"},{"nctId":"NCT05850832","phase":"PHASE2,PHASE3","title":"Efficacy of Esmolol Versus Magnesium Sulphate on Quality of Recovery in Patients Undergoing Laparoscopic Cholecystectomy: Randomized Controlled Study","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-10-05","conditions":["Esmolol Adverse Reaction"],"enrollment":60,"completionDate":"2023-04-10"},{"nctId":"NCT05635877","phase":"PHASE4","title":"Effects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients","status":"RECRUITING","sponsor":"Yongtao Sun","startDate":"2023-02-07","conditions":["Frailty","Esmolol","Myocardial Injury"],"enrollment":2000,"completionDate":"2026-12-30"},{"nctId":"NCT03743103","phase":"PHASE4","title":"Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)","status":"TERMINATED","sponsor":"Cristália Produtos Químicos Farmacêuticos Ltda.","startDate":"2019-04-18","conditions":["Hemorrhagic Stroke"],"enrollment":20,"completionDate":"2021-10-31"},{"nctId":"NCT05694585","phase":"PHASE4","title":"Effect of Esmolol on Perioperative Stress Reaction","status":"UNKNOWN","sponsor":"Xiumei Song","startDate":"2023-02-01","conditions":["Esmolol","Stress Reaction","Airway Obstruction","Catecholamine; Overproduction"],"enrollment":46,"completionDate":"2023-12-31"},{"nctId":"NCT05567822","phase":"NA","title":"The Impact of Esmolol Administration on Postoperative Recovery","status":"UNKNOWN","sponsor":"Aretaieion University Hospital","startDate":"2022-10-01","conditions":["Pain, Acute","Pain, Postoperative","Pain, Chronic Post-Surgical","Esmolol","Inguinal Hernia Repair","Analgesia","Nociceptive Pain"],"enrollment":70,"completionDate":"2024-10-01"},{"nctId":"NCT05430724","phase":"NA","title":"The Effects of Nicardipine and Esmolol Applied for Controlled Hypotension","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2022-05-12","conditions":["Hypotension","Surgery-Complications","Oxygen Deficiency"],"enrollment":80,"completionDate":"2022-08-30"},{"nctId":"NCT05389176","phase":"NA","title":"Effects of Heart Control at Different Stages in Patients of Septic Shock With Tachycardia","status":"UNKNOWN","sponsor":"Chinese Medical Association","startDate":"2022-07-01","conditions":["Septic Shock","Tachycardia"],"enrollment":96,"completionDate":"2024-06-30"},{"nctId":"NCT04234477","phase":"PHASE4","title":"Assessment of Intravenous Rate Control Response in Atrial Fibrillation Trial (AIRCRAFT)","status":"WITHDRAWN","sponsor":"Boston University","startDate":"2021-12","conditions":["Atrial Fibrillation"],"enrollment":0,"completionDate":"2022-06"},{"nctId":"NCT01422616","phase":"PHASE3","title":"Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)","status":"COMPLETED","sponsor":"The George Institute","startDate":"2012-03","conditions":["Ischemic Stroke","High Blood Pressure"],"enrollment":4587,"completionDate":"2018-08"},{"nctId":"NCT05073094","phase":"PHASE4","title":"Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy","status":"UNKNOWN","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2021-10-06","conditions":["Hypertrophic Obstructive Cardiomyopathy"],"enrollment":80,"completionDate":"2023-07-01"},{"nctId":"NCT04752111","phase":"PHASE4","title":"Dose Esmolol Infusion Have an Adjuvant Effect to TAP Block for Pain Control in Laparoscopic Cholecystectomy.","status":"COMPLETED","sponsor":"Benha University","startDate":"2021-01-19","conditions":["Postoperative Pain"],"enrollment":60,"completionDate":"2021-07-20"},{"nctId":"NCT02967029","phase":"PHASE4","title":"Effect of Controlled Hypotension on Cerebral Oxygen Saturation","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2016-11-01","conditions":["Hypotension Drug-Induced","Cerebral Oxygen Saturation"],"enrollment":150,"completionDate":"2017-08-01"},{"nctId":"NCT04948957","phase":"","title":"Changes in Cerebral Oxygenation and Cognitive Functions","status":"COMPLETED","sponsor":"Zonguldak Bulent Ecevit University","startDate":"2014-03-01","conditions":["Hypotension; Controlled","Cognitive Dysfunction"],"enrollment":40,"completionDate":"2016-08-01"},{"nctId":"NCT02369900","phase":"PHASE2","title":"Esmolol to Treat the Hemodynamic Effects of Septic Shock","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2015-03","conditions":["Septic Shock","Hypotension","Tachycardia"],"enrollment":40,"completionDate":"2019-12-31"},{"nctId":"NCT03661346","phase":"PHASE2","title":"Esmolol vs. Labetalol in Endoscopic Sinus Surgery","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2017-03-01","conditions":["Chronic Sinusitis"],"enrollment":28,"completionDate":"2018-03-30"},{"nctId":"NCT04046068","phase":"","title":"Multimodal Perioperative Pain Management: ComfortSafe Program","status":"UNKNOWN","sponsor":"Georgetown University","startDate":"2020-05-11","conditions":["Post-operative Pain","Post-operative Nausea and Vomiting","Respiratory Depression","Confusion Postoperative"],"enrollment":60,"completionDate":"2021-09"},{"nctId":"NCT04537767","phase":"NA","title":"The Effect of Esmolol on Patients With Sepsis","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-10-01","conditions":["Sepsis"],"enrollment":120,"completionDate":"2023-09-30"},{"nctId":"NCT04507165","phase":"NA","title":"Opioid-free Anesthesia in VATS Lung Resection","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2020-08","conditions":["Opioid Free Anesthesia"],"enrollment":100,"completionDate":"2022-07"},{"nctId":"NCT04260685","phase":"PHASE2","title":"Lidocaine Versus Esmolol for Optimizing Surgical Field Visibility","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-02-04","conditions":["Lumbar Disc Herniation"],"enrollment":70,"completionDate":"2020-06-30"},{"nctId":"NCT04014010","phase":"","title":"Machine Learning Modeling of Intraoperative Hemodynamic Predictors of Postoperative Outcomes","status":"COMPLETED","sponsor":"Janny Xue Chen Ke","startDate":"2013-01-01","conditions":["Perioperative/Postoperative Complications","Morbidity, Multiple","Surgery","Anesthesia","Death"],"enrollment":35000,"completionDate":"2017-12-31"},{"nctId":"NCT04306913","phase":"NA","title":"Outcome of Esmolol Potassium Cardioplegia Compared to Potassium Cardioplegia in Patients With Solitary Valvular Disease; Randomized Controlled Study","status":"UNKNOWN","sponsor":"Kasr El Aini Hospital","startDate":"2020-04","conditions":["Cardioplegia Solution Adverse Reaction"],"enrollment":80,"completionDate":"2020-09"},{"nctId":"NCT01114971","phase":"PHASE4","title":"Labetalol and Esmolol: Vital Signs and Post Operative Pain Management","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2009-09-03","conditions":["Laparoscopic Surgery"],"enrollment":75,"completionDate":"2018-07-31"},{"nctId":"NCT02997800","phase":"PHASE2","title":"The Effect of Intraoperative Labetalol on Time to Discharge","status":"COMPLETED","sponsor":"Dr. Robert Tanzola","startDate":"2012-11","conditions":["Bloodpressure","Heart Rate"],"enrollment":172,"completionDate":"2019-01"},{"nctId":"NCT04264286","phase":"PHASE4","title":"The Effects of Esmolol on the Hemodynamic Response to Orotracheal Extubation","status":"UNKNOWN","sponsor":"Hospital de Base","startDate":"2019-07-01","conditions":["Beta Blocker","Hemodynamic Instability"],"enrollment":80,"completionDate":"2020-07"},{"nctId":"NCT04086940","phase":"PHASE4","title":"Role of Intraoperative Beta Blocker for Morbid Obese Patients Undergoing Laparoscopic Bariatric Surgery","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-11","conditions":["Intraoperative Awareness","Postoperative Pain"],"enrollment":60,"completionDate":"2019-12"},{"nctId":"NCT02116868","phase":"NA","title":"Pupillary Reflex Measurement to Guide Intraoperative Analgesia During Laparoscopic Surgery","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2014-03","conditions":["Scheduled Laparoscopic Surgery"],"enrollment":100,"completionDate":"2018-04"},{"nctId":"NCT03533179","phase":"PHASE4","title":"Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition","status":"COMPLETED","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2018-06-01","conditions":["Drug Overdose","Overdose of Beta-adrenergic Blocking Drug"],"enrollment":10,"completionDate":"2019-10-01"},{"nctId":"NCT01824758","phase":"PHASE4","title":"Effect of Esmolol on Pain Due to Rocuronium","status":"COMPLETED","sponsor":"Ankara Diskapi Training and Research Hospital","startDate":"2013-03","conditions":["Injection Site Irritation"],"enrollment":90,"completionDate":"2013-05"},{"nctId":"NCT03965442","phase":"","title":"Effects of Intraoperative Esmolol on Post-mastectomy Pain Syndrome","status":"UNKNOWN","sponsor":"Hospital de Base","startDate":"2019-01-01","conditions":["Post-mastectomy Pain Syndrome"],"enrollment":66,"completionDate":"2019-07-31"},{"nctId":"NCT03612492","phase":"PHASE4","title":"The Effects of Lidocaine and Esmolol on Attenuation of Hemodynamic Response to Orotracheal Intubation","status":"UNKNOWN","sponsor":"Hospital de Base","startDate":"2018-07-01","conditions":["Hemodynamic Instability"],"enrollment":80,"completionDate":"2019-07-31"},{"nctId":"NCT03892512","phase":"PHASE1,PHASE2","title":"Dexmedetomidine and Esmolol Early Post Operative Cognitive Dysfunction","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2019-04","conditions":["Cognitive Dysfunction"],"enrollment":58,"completionDate":"2019-12"},{"nctId":"NCT01212874","phase":"NA","title":"Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery","status":"COMPLETED","sponsor":"Loma Linda University","startDate":"2010-12","conditions":["Hypertension"],"enrollment":70,"completionDate":"2014-06"},{"nctId":"NCT03208257","phase":"PHASE2","title":"Esmolol to Control Adrenergic Storm in Septic Shock- ROLL-IN 2","status":"UNKNOWN","sponsor":"Samuel Brown","startDate":"2017-08-07","conditions":["Septic Shock"],"enrollment":10,"completionDate":"2021-06"},{"nctId":"NCT02841241","phase":"PHASE2","title":"Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia","status":"COMPLETED","sponsor":"Intermountain Health Care, Inc.","startDate":"2016-04","conditions":["Septic Shock"],"enrollment":7,"completionDate":"2017-03"},{"nctId":"NCT02327923","phase":"PHASE4","title":"Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2015-01","conditions":["Gall Stone Disease"],"enrollment":90,"completionDate":"2016-04"},{"nctId":"NCT01544959","phase":"NA","title":"Postoperative Analgesia Impact of Narcotic Free Anesthesia","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2010-01","conditions":["Pain, Postoperative","Breast Cancer","Postoperative Nausea and Vomiting"],"enrollment":84,"completionDate":"2018-05"},{"nctId":"NCT00959569","phase":"PHASE4","title":"Esmolol in Cardiac Surgery","status":"COMPLETED","sponsor":"Università Vita-Salute San Raffaele","startDate":"2009-08","conditions":["Cardiac Surgery"],"enrollment":200,"completionDate":"2018-06"},{"nctId":"NCT03646773","phase":"","title":"Microvascular Effects of Intravenous Esmolol During Postoperative Atrial Fibrillation","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-12","conditions":["Postoperative Atrial Fibrillation"],"enrollment":25,"completionDate":"2016-11"},{"nctId":"NCT02609152","phase":"PHASE3","title":"Effect of a Continuous Infusion of Esmolol on Stroke Volume in Patients With Hyperdynamic Vasoplegic Septic Shock","status":"WITHDRAWN","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2016-07","conditions":["Shock, Septic"],"enrollment":0,"completionDate":"2017-08"},{"nctId":"NCT03347968","phase":"PHASE1","title":"Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2017-11-27","conditions":["Healthy Volunteers"],"enrollment":22,"completionDate":"2018-04-09"},{"nctId":"NCT00756236","phase":"NA","title":"A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2008-10","conditions":["Myocardial Ischemia"],"enrollment":60,"completionDate":"2015-09-02"},{"nctId":"NCT02563288","phase":"PHASE3","title":"Esmolol Versus Dexmedetomidine During Intracranial Procedures","status":"UNKNOWN","sponsor":"George Papanicolaou Hospital","startDate":"2016-08","conditions":["Intracranial Aneurysm","Intracranial Neoplasms"],"enrollment":60,"completionDate":"2017-10"},{"nctId":"NCT01343329","phase":"PHASE1,PHASE2","title":"Controlling Hyperadrenergic Activity in Neurologic Injury","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2011-07","conditions":["Traumatic Brain Injury","Dysautonomia"],"enrollment":0,"completionDate":"2014-02-14"},{"nctId":"NCT02466542","phase":"PHASE4","title":"Analgesic Effect of Intraoperative Esmolol in Mastectomies","status":"COMPLETED","sponsor":"Hospital de Base","startDate":"2015-06","conditions":["Postoperative Pain"],"enrollment":60,"completionDate":"2017-02"},{"nctId":"NCT01782898","phase":"NA","title":"The Effect of Intraoperative Esmolol to Improve Postoperative Quality of Recovery and Pain After Ambulatory Surgery","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2013-01","conditions":["Pain"],"enrollment":70,"completionDate":"2014-12"},{"nctId":"NCT01114997","phase":"PHASE4","title":"Effect of Lidocaine and Esmolol to Improve the Quality of Recovery","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2010-04","conditions":["Pain","Constipation","Nausea","Vomiting"],"enrollment":32,"completionDate":"2015-06"},{"nctId":"NCT01179113","phase":"PHASE4","title":"Esmolol Infusion During Laminectomy: Effect on Quality of Recovery","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2011-06","conditions":["Laminectomy"],"enrollment":33,"completionDate":"2015-05"},{"nctId":"NCT00922467","phase":"PHASE3","title":"Influence of Esmolol on a Closed-Loop Anesthesia System","status":"TERMINATED","sponsor":"Hopital Foch","startDate":"2009-06","conditions":["Anesthesia"],"enrollment":15,"completionDate":"2011-12"},{"nctId":"NCT02844894","phase":"PHASE4","title":"Hemodynamic Response to Intubation","status":"UNKNOWN","sponsor":"Ufuk University","startDate":"2016-06","conditions":["Intubation"],"enrollment":60,"completionDate":"2016-09"},{"nctId":"NCT02842983","phase":"PHASE2,PHASE3","title":"Pilot Study: Echocardiographic and Hemodynamic Effects of Esmolol in Septic Shock Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2014-12","conditions":["Shock, Septic"],"enrollment":36,"completionDate":"2016-12"},{"nctId":"NCT02794025","phase":"NA","title":"The Effect of Esmolol on Clinical Prognosis of Patients With Severe Sepsis","status":"COMPLETED","sponsor":"Fujian Provincial Hospital","startDate":"2010-01","conditions":["Severe Sepsis"],"enrollment":151,"completionDate":"2013-01"},{"nctId":"NCT01885364","phase":"NA","title":"Esmolol Pretreatment on Pain During Injection of Propofol","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2015-06","conditions":["Pain"],"enrollment":120,"completionDate":"2015-12"},{"nctId":"NCT02068287","phase":"PHASE2","title":"Esmolol Effects on Heart and Inflammation in Septic Shock","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2013-12","conditions":["Septic Shock"],"enrollment":25,"completionDate":"2017-06"},{"nctId":"NCT02188888","phase":"","title":"Echocardiographic and Arterial Pressure Waveform Changes After Reducing Heart Rate With Esmolol in Septic Shock Patients","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2013-12","conditions":["Tachycardia","Septic Shock"],"enrollment":45,"completionDate":"2014-06"},{"nctId":"NCT02455440","phase":"PHASE3","title":"Esmolol Infusion in Patients Undergoing Craniotomy","status":"COMPLETED","sponsor":"George Papanicolaou Hospital","startDate":"2014-03","conditions":["Cerebral Arterial Disease","Cerebral Aneurysm"],"enrollment":50,"completionDate":"2015-07"},{"nctId":"NCT01741519","phase":"PHASE1","title":"Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2012-12","conditions":["Healthy"],"enrollment":14,"completionDate":"2013-01"},{"nctId":"NCT01404767","phase":"PHASE4","title":"Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol","status":"TERMINATED","sponsor":"University Health Network, Toronto","startDate":"2011-04","conditions":["Vascular Disease","Hypertension","Angina","Cardiac Disease"],"enrollment":20,"completionDate":"2013-12"},{"nctId":"NCT01628562","phase":"PHASE4","title":"A Comparison of the Perioperative Hemodynamic Effects of Remifentanil and Esmolol in Intracranial Surgery","status":"COMPLETED","sponsor":"Diskapi Teaching and Research Hospital","startDate":"2012-06","conditions":["Tachycardia","Hypertension","Myocardial Ischemia"],"enrollment":40,"completionDate":"2014-09"},{"nctId":"NCT01232400","phase":"NA","title":"Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2014-07","conditions":["Subarachnoid Hemorrhage"],"enrollment":0,"completionDate":"2016-08"},{"nctId":"NCT02319161","phase":"","title":"Comparison of Calcium Channel Blockers and Beta Blockers on Tourniquet-induced Hypertension During Intravenous Regional Anesthesia","status":"COMPLETED","sponsor":"Ankara University","startDate":"2014-06","conditions":["Hypertension"],"enrollment":50,"completionDate":"2014-10"},{"nctId":"NCT01208402","phase":"PHASE3","title":"Esmolol for Treatment of Perioperative Tachycardia","status":"TERMINATED","sponsor":"Duke University","startDate":"2010-09","conditions":["High-risk, Non-cardiovascular Surgeries"],"enrollment":76,"completionDate":"2013-07"},{"nctId":"NCT02062333","phase":"PHASE4","title":"The Effects of the Drugs Used in Hypotensive Anaesthesia on Cochlea","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2014-01","conditions":["Anesthesia; Adverse Effect","Reflex, Abnormal","Tinnitus, Spontaneous Oto-Acoustic Emission"],"enrollment":47,"completionDate":"2014-11"},{"nctId":"NCT01951950","phase":"PHASE1","title":"Nicardipine vs Esmolol Craniotomy Emergence","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2013-09","conditions":["Brain Tumors"],"enrollment":40,"completionDate":"2014-05"},{"nctId":"NCT00713401","phase":"PHASE2","title":"Safety Study of Tecadenoson to Treat Atrial Fibrillation","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-02","conditions":["Atrial Fibrillation"],"enrollment":21,"completionDate":"2008-07"},{"nctId":"NCT00716079","phase":"NA","title":"The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial","status":"COMPLETED","sponsor":"The George Institute","startDate":"2008-09","conditions":["Intracerebral Hemorrhage","Stroke","Hypertension"],"enrollment":2839,"completionDate":"2012-12"},{"nctId":"NCT01275911","phase":"NA","title":"Non-opioid Analgesia for Fast-track Surgery","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2009-01","conditions":["Pain"],"enrollment":40,"completionDate":"2010-08"},{"nctId":"NCT01231698","phase":"PHASE2","title":"Heart Rate Control With Esmolol in Septic Shock","status":"COMPLETED","sponsor":"Andrea Morelli","startDate":"2010-12","conditions":["Septic Shock"],"enrollment":154,"completionDate":"2012-07"},{"nctId":"NCT01752959","phase":"PHASE4","title":"A Comparison of Esmolol and Remifentanil to Reduce Blood Loss","status":"UNKNOWN","sponsor":"Diskapi Teaching and Research Hospital","startDate":"2012-07","conditions":["Deviation Septum Nasal"],"enrollment":60,"completionDate":"2012-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Esmolol Hydrochloride"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"esmolol hydrochloride"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"esmolol hydrochloride in sodium chloride"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"BREVIBLOC"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Brevibloc"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"ESMOLOL HYDROCHLORIDE"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Esmolol"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Esmolol Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"ESMOLOL HYDROCHLORIDE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Esmolol Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"esmolol hydrochloride"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147837","MMSL":"3762","NDDF":"001861","UNII":"MDY902UXSR","VUID":"4019746","CHEBI":"CHEBI:4856","VANDF":"4019349","INN_ID":"5365","RXNORM":"151448","UMLSCUI":"C0116569","chemblId":"CHEMBL1201115","ChEMBL_ID":"CHEMBL768","KEGG_DRUG":"D00644","DRUGBANK_ID":"DB00187","PUBCHEM_CID":"59768","SNOMEDCT_US":"35318005","IUPHAR_LIGAND_ID":"7178","SECONDARY_CAS_RN":"81161-17-3","MESH_SUPPLEMENTAL_RECORD_UI":"C036604"},"formularyStatus":[],"originalProduct":{"form":"INJECTION","route":"INTRAVENOUS","company":"Baxter Healthcare Corporation","brandName":"BREVIBLOC","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1986-","companyName":"Baxter Hlthcare","relationship":"Original Developer"},{"period":"present","companyName":"Hq Spclt Pharma","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.15 hours","clearance":"290.0 mL/min/kg","fractionUnbound":"0.59%","volumeOfDistribution":"1.2 L/kg"},"publicationCount":1618,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C07AB09","allCodes":["C07AB09"]},"biosimilarFilings":[],"originalDeveloper":"Baxter Hlthcare","recentPublications":[{"date":"2026 Mar 23","pmid":"41870838","title":"What If We Let It Fibrillate? New Perspective on Atrial Fibrillation in Sepsis.","journal":"Current medical science"},{"date":"2026 Feb","pmid":"41835717","title":"Severe Hypoglycemia-Induced Seizure in a Four-Year-Old Following Initiation of Nadolol for Supraventricular Tachycardia.","journal":"Cureus"},{"date":"2026 Feb 27","pmid":"41763668","title":"Anaesthetic management of neurogenic atrial fibrillation with rapid ventricular response in a patient undergoing decompressive hemicraniectomy.","journal":"BMJ case reports"},{"date":"2026 Feb","pmid":"41736776","title":"Vasoactive drugs and the distribution of crystalloid fluid during acute sepsis.","journal":"Journal of intensive medicine"},{"date":"2026 Feb 14","pmid":"41689856","title":"Inhibitory effects and molecular interaction analysis of emergency cardiac drugs on human serum paraoxonase 1: an integrated in vitro and in silico approach.","journal":"Archives of physiology and biochemistry"}],"companionDiagnostics":[],"genericManufacturers":10,"_genericFilersChecked":true,"genericManufacturerList":["Am Regent","Amneal","Eugia Pharma","Fresenius Kabi Usa","Gland","Hikma","Hq Spclt Pharma","Mylan Institutional","Mylan Labs Ltd","Sagent Pharms Inc"],"status":"withdrawn","companyName":"Hq Spclt Pharma","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1986","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1986-12-31T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1989-05-26T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":"NDA019386"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-04-07T00:00:00.000Z","mah":"HQ SPCLT PHARMA","brand_name_local":null,"application_number":"NDA205703"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-03-19T00:00:00.000Z","mah":"MYLAN LABS LTD","brand_name_local":null,"application_number":"ANDA206608"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-06-04T00:00:00.000Z","mah":"HQ SPCLT PHARMA","brand_name_local":null,"application_number":"ANDA214172"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-07-09T00:00:00.000Z","mah":"EUGIA PHARMA","brand_name_local":null,"application_number":"ANDA216244"},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:51:18.215831+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}